BioMarin Pharmaceutical Inc.
BMRN
$65.99
$0.921.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 72.97M | 268.74M | 348.90M | 520.42M | 657.24M |
| Total Depreciation and Amortization | 145.57M | 66.50M | 72.16M | 82.73M | 83.25M |
| Total Amortization of Deferred Charges | 7.40M | 7.40M | 7.40M | -- | -- |
| Total Other Non-Cash Items | 691.59M | 695.74M | 693.20M | 523.59M | 318.91M |
| Change in Net Operating Assets | -60.45M | -164.13M | -293.66M | -212.76M | -292.62M |
| Cash from Operations | 857.09M | 874.25M | 827.99M | 913.98M | 766.77M |
| Capital Expenditure | -118.91M | -107.19M | -103.04M | -81.85M | -71.86M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -5.35B | -285.19M | -285.19M | -285.19M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 721.97M | 731.91M | -26.01M | 71.65M | 91.28M |
| Cash from Investing | -4.75B | 339.52M | -414.24M | -295.39M | 19.42M |
| Total Debt Issued | 3.65B | 850.00M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | -494.99M |
| Issuance of Common Stock | 13.41M | 14.46M | 14.46M | 15.58M | 20.37M |
| Repurchase of Common Stock | -44.38M | -45.37M | -55.97M | -58.17M | -61.91M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -66.49M | -9.54M | -889.00K | -94.00K | -3.12M |
| Cash from Financing | 3.55B | 809.55M | -42.39M | -42.69M | -539.65M |
| Foreign Exchange rate Adjustments | 328.00K | 305.00K | -2.52M | -1.24M | -4.88M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -339.81M | 2.02B | 368.84M | 574.66M | 241.67M |